Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Investor Presentation [12-2024]

<< Previous

Bullboard Posts

Next >>

Comment by TommyNickelson Dec 09, 2024 8:44am

182 Views

Post# 36352323

RE:Investor Presentation [12-2024]

Clearly the FDA wants the study completed. They haven't recruited 4 new sites for no reason. Roger likely was gambling that 75 would be good enough. As wr have been saying, Theralase is not sufficiently bankrolled. 4 new sites and no money for new patients.

They have to get the money and then recruit the patients. Will 25 more patients be completed by end of Q2? Doubtful, hence the 2027 deadline.

If you are lucky, the next 25 are treated by the end of Q3 / early Q4.

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly